RTOG: Hormone Therapy Increases Survival When Combined With Radiation Therapy
Zaltrap Shows Improvement in Survival In Stage IV Metastatic Colorectal Cancer
Trial: Decitabine Improves Survival in Myeloid Leukemia
Gleevec For KIT-positive Tumors Shows 92 Percent Overall Survival
VEGF Levels Can Predict Tumor’s Resistance to Avastin
More Patients Get Screened, Colorectal Death Rates Drop
Revlimid Shows 91 Percent Response in Non-Hodgkin’s
Revlimid Also Demonstrates Response in Mantle Cell
FPD-R Regimen Well-Tolerated, With 63 Percent Complete Response
Overall Cancer Mortality Rates Higher For Men Than Women
New Model For Risk Assessment Includes Alcohol, Exercise, Weight
Researchers Identify Five Genes Associated With Melanoma Risk
Stereotactic Body Radiotherapy Could Improve Overall Survival
CMS Issues Coverage Decision For Provenge in Prostate Cancer
Clinical Trials Approved By NCI CTEP Last Month
Approval Granted For New Formulation of Lupron Depot
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- What happened at FDA? Replimune approval raises questions
- I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.” - Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial
